康泰生物预计2025年实现海外业务收入9883.53万元 全球化创新进展显著

Group 1 - The core viewpoint of the article highlights Shenzhen Kangtai Biological Products Co., Ltd.'s transformation into a global innovative biopharmaceutical company, with significant growth in R&D investment and overseas business revenue [1][2] - In 2025, the company expects a net profit attributable to shareholders of between 49 million to 73 million yuan, with overseas business revenue reaching approximately 98.84 million yuan, reflecting a year-on-year growth of 859.40% [1] - R&D investment is projected to be around 633 million yuan, marking an 11.25% increase compared to the previous year [1] Group 2 - The company has made key progress in expanding its overseas market, with multiple core vaccine products obtaining overseas GMP certification or registration, covering over 20 countries [2] - Kangtai Biological is leveraging AI technology to enhance vaccine innovation, participating in industry exchanges and establishing a key laboratory in collaboration with the Chinese Academy of Sciences [2] - The company aims to accelerate its transformation by focusing on R&D-driven strategies, deepening international layouts, and embracing AI to enhance the entire vaccine development and production process [3]